NICE backing for Astella’s Xospata
The drug is considered a cost-effective treatment for relapsed or refractory FLT3 mutation-positive acute myeloid leukaemia
Read More
Tag: FLT3 mutation-positive
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
